Tesaro (TSRO) Faces Near-Term Risks to Key Drug - Report

May 6, 2013 9:58 AM EDT
Tesaro Inc. (NASDAQ: TSRO) was the target of a negative blog post at SeekingAlpha Monday. Author Richard Pearson said while enthusiasm has built for still far-off cancer drug Niraparib, the risk for the company's lead drug Rolapitant is surging.

Pearson said by the time Rolapitant even comes to market in 2015, Merck's (NYSE: MRK) Emend will already be marketed as a generic drug. Another problem for Rolapitant - which Pearson said is more severe - is that Swiss company Helsinn recently completed phase III trials of its own CINV, Netupitant, which actually combines the action of an NK-1 and a 5-HT3. Analysts have largely ignored the market potential for Netupitant but trial results are widely expected to be positive and could be announced at or before the May ASCO meeting.

Near-term challenges to Rolapitant could see the shares drop back below $21 in the coming weeks, Pearson said.

Shares of TSRO are down 1 percent early Monday to $29.10.

Link to SA Article


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Insiders' Blog, Trader Talk